Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) becomes gradually the most frequent liver disease in the world. Expert teams in the USA, Western Europe, and Russia give pride of place within the NAFLD treatment regime to lifestyle modification including the optimization of physical activity, diet and, as...
Saved in:
Published in | Medical Council no. 3; pp. 54 - 59 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English Russian |
Published |
Remedium Group LLC
20.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Non-alcoholic fatty liver disease (NAFLD) becomes gradually the most frequent liver disease in the world. Expert teams in the USA, Western Europe, and Russia give pride of place within the NAFLD treatment regime to lifestyle modification including the optimization of physical activity, diet and, as a consequence, the BMI reduction. However, it is often difficult for the practitioner to motivate the patients to change their lifestyle and eating habits. Due to this, it is extremely important to use a pharmacologic therapy aimed at weight loss, reducing insulin resistance and repopulating the severely damaged liver parenchyma. By now ursodeoxycholic acid drugs (Ursosan) have been proved to be highly effective in treating NAFLD in clinical practice, having a significant impact on several pathogenetic mechanisms of this disease. |
---|---|
ISSN: | 2079-701X 2658-5790 |
DOI: | 10.21518/2079-701X-2018-3-54-59 |